Director at PAVmed (PAVM) receives 13,930 restricted stock shares

Rhea-AI Filing Summary

Glennon Michael J reported acquisition or exercise transactions in this Form 4 filing.

PAVmed Inc. director Michael J. Glennon reported an award of 13,930 shares of restricted common stock as equity compensation. The shares were granted at no cash cost to him under the company’s Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan and have a single vesting date of May 20, 2029. The restricted stock is subject to forfeiture if he does not complete the required service period. Following this grant, Glennon directly holds 21,653 shares of PAVmed common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Glennon Michael J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common stock	13,930	$0.00	--

Holdings After Transaction: Common stock — 21,653 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Restricted stock grant: 13,930 shares Grant price: $0.00 per share Shares held after grant: 21,653 shares +1 more

4 metrics

Restricted stock grant 13,930 shares Equity award of common stock

Grant price $0.00 per share Compensation grant, no cash paid

Shares held after grant 21,653 shares Direct holdings following transaction

Vesting date May 20, 2029 Single vesting date for restricted stock

Key Terms

restricted stock, Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan, vesting, forfeiture

4 terms

restricted stock financial

"Represents restricted stock granted to the reporting person under the issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan financial

"under the issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2029"

vesting financial

"with a single vesting date of May 20, 2029"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

forfeiture financial

"Such restricted stock is subject to forfeiture if the requisite service period is not completed"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Glennon Michael J

(Last) (First) (Middle)

360 MADISON AVENUE

25TH FLOOR

(Street)

NEW YORK NEW YORK 10017

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PAVmed Inc. [ PAVM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	04/02/2026		A		13,930(1)	A	$0(1)	21,653	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock granted to the reporting person under the issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed.

	/s/ Michael A. Gordon, by power of attorney	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PAVmed (PAVM) director Michael J. Glennon report?

Michael J. Glennon reported receiving 13,930 shares of restricted PAVmed common stock as an equity award. The grant carries no cash purchase price and is part of his director compensation, increasing his direct holdings to 21,653 shares after the transaction.

Is the recent PAVmed (PAVM) stock grant to Michael J. Glennon an open-market purchase?

No, the 13,930-share transaction is a restricted stock grant, not an open-market purchase. It was awarded under PAVmed’s long-term incentive equity plan at a price of $0.00 per share as compensation for service, rather than a discretionary stock buy.

When do Michael J. Glennon’s new PAVmed (PAVM) restricted shares vest?

The 13,930 restricted shares granted to Michael J. Glennon vest on May 20, 2029. Until that single vesting date, the award remains subject to forfeiture if the required service period under the company’s long-term incentive equity plan is not fully completed.

How many PAVmed (PAVM) shares does Michael J. Glennon hold after this Form 4 filing?

After the restricted stock grant, Michael J. Glennon directly holds 21,653 shares of PAVmed common stock. This total includes the newly awarded 13,930 restricted shares, which will only fully vest on May 20, 2029, assuming service conditions are met.

What plan governed Michael J. Glennon’s restricted stock grant at PAVmed (PAVM)?

The restricted stock grant was issued under PAVmed’s Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan. This plan provides equity-based compensation, with Glennon’s 13,930-share award vesting on May 20, 2029 and subject to forfeiture if service requirements are not satisfied.